The biosimilar month in review highlights ranibizumab biosimilars for the treatment of nAMD, Optum Rx’s decision to recognize subcutaneous adalimumab-adbm as a preferred brand, and the cost-saving benefits of biosimilars for patients.
The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.